Utilities Registry – Page 3 – Center for Health Decision Science

Filter results using search terms, or by selecting one or more valuation, condition, or population.

Valuation

Population

Condition

Viewing 21 - 30 of 44 results

Title	Year(s) of data collection	Valuation Method	Country	Condition
Selection of autoimmune disease health state utilities (Saccà F et al., J Neurol. 2023. doi:10.1007/s00415-022-11517-w)	2018 - 2020	EQ-5D-5L	Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, United Kingdom of Great Britain and Northern Ireland, United States of America	Myasthenia gravis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics 167 participants in phase 3 RCT of efgartigimod, ADAPT trial
Title Selection of mental health health state utilities (Shoji M et al., BMC Psychiatry. 2023. doi:10.1186/s12888-023-04602-5)	Year(s) of data collection 2019 - 2020	Valuation Method EQ-5D-5L	Country Japan	Condition Depression
DOI 10.7910/DVN/QNA5ZF Author(s) Registry, Utilities Description Health state utilities for mental health conditions Sample Characteristics 31 participants in a non-randomized controlled, interventional study investigating effects of community pharmacists' cognitive behavioral therapy based interventions on medication adherence and relevant indicators in patients with depression
Title Selection of mental health health state utilities (Denee T et al., J Affect Disord. 2023. doi:10.1016/j.jad.2022.12.135)	Year(s) of data collection 2019	Valuation Method EQ-5D-5L	Country United Kingdom of Great Britain and Northern Ireland	Condition Depression - caregivers
DOI 10.7910/DVN/QNA5ZF Author(s) Registry, Utilities Description Health state utilities for mental health conditions Sample Characteristics 99 carers of individuals with symptomatic treatment-resistant depression or in remission post-TRD
Title Selection of oncology health state utilities (Katanyoo K et al., Expert Rev Pharmacoecon Outcomes Res. 2022. doi:10.1080/14737167.2021.1906224)	Year(s) of data collection 2019	Valuation Method EQ-5D-3L, EQ-5D-5L, TTO	Country Thailand	Condition Cervical cancer
DOI 10.7910/DVN/L4V2LU Author(s) Registry, Utilities Description Health state utilities for oncology conditions Sample Characteristics 194 cross-sectional study patients with locally advanced cervical cancer
Title Selection of oncology health state utilities (Clavo B et al., Int J Environ Res Public Health. 2023. doi:10.3390/ijerph20021479)	Year(s) of data collection 2019 - 2022	Valuation Method EQ-5D-5L	Country Spain	Condition Symptomatic Cancer Survivor
DOI 10.7910/DVN/L4V2LU Author(s) Registry, Utilities Description Health state utilities for oncology conditions Sample Characteristics 26 patients with persistent or refractory side effects of cancer treatments to investigate the effects of ozone treatment
Title Selection of general population health health state utilities (McGrath A et al., Int J Environ Res Public Health. 2022. doi:10.3390/ijerph19042204)	Year(s) of data collection 2019	Valuation Method SF-6D	Country Ireland	Condition General population health
DOI 10.7910/DVN/OE5E2K Author(s) Registry, Utilities Description Health state utilities for general population health conditions Sample Characteristics 421 participants in the ‘Sheds for Life’, a 10-week men’s health initiative
Title Selection of general population health health state utilities (Xie S et al., Eur J Health Econ. 2023. doi:10.1007/s10198-023-01566-x)	Year(s) of data collection 2019	Valuation Method EQ-5D-5L, SF-6Dv2	Country China	Condition General population health
DOI 10.7910/DVN/OE5E2K Author(s) Registry, Utilities Description Health state utilities for general population health conditions Sample Characteristics 3320 participants from the Chinese general population
Title Selection of autoimmune disease health state utilities (Dewilde S et al., Adv Ther. 2023. doi:10.1007/s12325-023-02437-w)	Year(s) of data collection 2019 - 2022	Valuation Method EQ-5D-5L, HUI3	Country Canada, Denmark, France, Germany, Italy, Japan, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America	Condition Myasthenia gravis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics 1299 participants (EQ-5D-5L) and 549 participants (HUI3) from MyRealWorld-MG study
Title Selection of COVID-19 health state utilities (Rosa RG et al., Intensive Care Med. 2023. doi:10.1007/s00134-022-06953-1)	Year(s) of data collection 2020 - 2022	Valuation Method EQ-5D-3L	Country Brazil	Condition COVID-19
DOI 10.7910/DVN/MJ4J77 Author(s) Registry, Utilities Description Health state utilities for states related to COVID-19 Sample Characteristics 1156 adults post-hospitalization COVID-19 patients
Title Selection of COVID-19 health state utilities (Granholm A et al. Acta Anaesthesiol Scand 2023. doi:10.1111/aas.14231)	Year(s) of data collection 2020 - 2021	Valuation Method EQ-5D-5L	Country Denmark, India, Sweden, Switzerland	Condition COVID-19
DOI 10.7910/DVN/MJ4J77 Author(s) Registry, Utilities Description Health state utilities for states related to COVID-19 Sample Characteristics 982 patients in COVID STEROID 2 trial

← Previous results Next results →